FREQUENTLY ASKED QUESTIONS
What is the official ID of this bill?
The official print number for this legislation is 119_HR_4780.
Which chamber initiated this legislation?
This legislation was initiated in the House of Representatives.
When did the legislative process begin?
The process officially started on 2025-07-29.
What are the main provisions?
Key points include:
- Establishes a Chief Pharmaceutical Trade Negotiator to advocate for US pharmaceutical manufacturers and consumers.
- Requires annual reporting and identification of countries engaging in unfair pricing practices that harm innovation and drug access in the US.
- Mandates a response plan for adverse trade actions, including potential trade investigations, to protect American patients and taxpayers.
What is the specific legal status?
The current status is Introduced.
Where can I read the full text of this legislation?
The full official text is available at:
View full text
Who is the primary sponsor?
The primary sponsor is Rep. Arrington, Jodey C. [R-TX-19].
What is the latest detailed status?
The latest detailed status is: Referred to the House Committee on Ways and Means.
Is this summary verified?
Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.
What is the impact of this bill?
We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.